Indian court cracks down on 'Bolar exception' loophole to fortify global patent rights
By Freny Patel ( June 10, 2026, 02:14 GMT | Insight) -- India's Madras High Court has ruled that generic drug makers cannot rely on the statutory Bolar exception to export patented active pharmaceutical ingredients unless they can demonstrate that the exports were connected to regulatory approval activities.In a judgment with significant ramifications for the pharmaceutical industry, an Indian court has ruled that generic drug makers cannot use the statutory "Bolar exception" as a blanket shield to export patented active pharmaceutical ingredients, or APIs, unless they provide concrete, verifiable proof of regulatory intent....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.